Tyme Technologies Inc (NASDAQ:TYME) Major Shareholder Michael Demurjian Sells 20,000 Shares of Stock

Tyme Technologies Inc (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the company’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $1.03, for a total value of $20,600.00. Following the sale, the insider now owns 25,278,546 shares in the company, valued at approximately $26,036,902.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Tuesday, September 8th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.02, for a total value of $20,400.00.
  • On Wednesday, September 2nd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.04, for a total value of $20,800.00.
  • On Monday, August 24th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.17, for a total value of $23,400.00.
  • On Monday, August 17th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.29, for a total value of $25,800.00.
  • On Monday, August 10th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.30, for a total value of $26,000.00.
  • On Monday, August 3rd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.28, for a total value of $25,600.00.
  • On Monday, July 27th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.22, for a total value of $24,400.00.
  • On Monday, July 20th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.24, for a total value of $24,800.00.
  • On Monday, July 13th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.20, for a total value of $24,000.00.
  • On Monday, July 6th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.32, for a total value of $26,400.00.

Shares of Tyme Technologies stock traded up $0.02 on Wednesday, hitting $1.05. The stock had a trading volume of 1,871 shares, compared to its average volume of 767,738. Tyme Technologies Inc has a twelve month low of $0.86 and a twelve month high of $2.04. The business’s 50 day moving average is $1.16 and its two-hundred day moving average is $1.25. The stock has a market cap of $130.69 million, a price-to-earnings ratio of -4.68 and a beta of 0.84.

Large investors have recently modified their holdings of the stock. Advisor Group Holdings Inc. acquired a new stake in Tyme Technologies during the first quarter worth approximately $28,000. Lido Advisors LLC bought a new stake in Tyme Technologies during the second quarter worth $29,000. Jane Street Group LLC bought a new stake in Tyme Technologies during the second quarter worth $44,000. Spark Investment Management LLC bought a new position in shares of Tyme Technologies in the 1st quarter valued at $60,000. Finally, Pathstone Family Office LLC bought a new position in shares of Tyme Technologies in the 1st quarter valued at $99,000. 14.00% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently commented on the company. Zacks Investment Research raised Tyme Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, July 21st. HC Wainwright reaffirmed a “buy” rating and issued a $9.50 target price on shares of Tyme Technologies in a research report on Thursday, May 21st. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Tyme Technologies in a research report on Monday, June 29th.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Featured Article: Return on Investment (ROI) Defined, Explained

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.